Hyperdopaminergic tone in HIV-1 protein treated rats and cocaine sensitization

Journal of Neurochemistry

Volumn 115, Issue 4, 2010, Pages 885-896

  Ferris, Mark J ^a   Frederick Duus, Danielle ^b   Fadel, Jim ^b   Mactutus, Charles F ^a   Booze, Rosemarie M ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cocaine; Dopamine; Dopamine transporter; HIV 1; Sensitization; Tat

Indexed keywords

COCAINE; DOPAMINE; DOPAMINE TRANSPORTER; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; POTASSIUM; PROTEIN TAT 1-86; RECOMBINANT PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COCAINE DEPENDENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG SENSITIZATION; DRUG USE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERDOPAMINERGIC ACTIVITY; INFUSION; LOCOMOTION; MALE; METABOLITE; MICRODIALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; UPREGULATION;

ANIMALS; COCAINE; COCAINE-RELATED DISORDERS; DOPAMINE; HIV-1; MALE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TIME FACTORS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; RATTUS;

EID: 77958561328     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06968.x     Document Type: Article

References (50)

1. Aksenov M. Y., Aksenova M. V., Silvers J. M., Mactutus C. F. and Booze R. M. (2008) Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428, on HIV-1 Tat toxicity in rat fetal midbrain neurons. Neurotoxicology 29, 971-977.
2. Aksenova M. V., Silvers J. M., Aksenov M. Y., Nath A., Ray P. D., Mactutus C. F. and Booze R. M. (2006) HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci. Lett. 395, 235-239.
3. Argilli E., Sibley D. R., Malenka R. C., England P. M. and Bonci A. (2008) Mechanism and time course of cocaine-induced long-term potentiation in the ventral tegmental area. J. Neurosci. 28, 9092-9100.
4. Aylward E. H., Henderer J. D., Mcarthur J. C., Brettschneider P. D., Harris G. J., Barta P. E. and Pearlson G. D. (1993) Reduced basal ganglia volume in HIV-1 associated dementia - results from quantitative neuroimaging. Neurology 43, 2099-2104.
5. Baggaley R. F., Boily M. C., White R. G. and Alary M. (2006) Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 20, 805-812.
6. Bansal A. K., Mactutus C. F., Nath A., Maragos W., Hauser K. F. and Booze R. M. (2000) Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res. 879, 42-49.
7. Buttner A., Kroehling C., Mall G., Penning R. and Weis S. (2005) Alterations of the vascular basal lamina in the cerebral cortex in drug abuse: a combined morphometric and immunohistochemical investigation. Drug Alcohol Depend. 79, 63-70.
8. Cass W. A., Harned M. E., Peters L. E., Nath A. and Maragos W. F. (2003) HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res. 984, 133-142.
9. Castaneda T. R., Prado B. M., Prieto D. and Mora F. (2004) Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light. J. Pineal Res. 36, 177-185.
10. Chang L., Wang G. J., Volkow N. D., Ernst T., Telang F., Logan J. and Fowler J. S. (2008) Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neuroimage 42, 869-878.
11. Crits-Christoph P., Newberg A., Wintering N., Ploessl K., Gibbons M. B. C., Ring-Kurtz S., Gallop R. and Present J. (2008) Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend. 98, 70-76.
12. Czub S., Koutsilieri E., Sopper S. et al. (2001) Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol. 101, 85-91.
13. Czub S., Czub M., Koutsilieri E., Sopper S., Villinger F., Muller J. G., Stahl-Hennig C., Riederer P., Ter Meulen V. and Gosztonyi G. (2004) Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs. Acta Neuropathol. 107, 216-226.
14. Di Rocco A., Bottiglieri T., Dorfman D., Werner P., Morrison C. and Simpson D. (2000) Decreased homovanilic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clin. Neuropharmacol. 23, 190-194.
15. Everall I. P., Hansen L. A. and Masliah E. (2005) The shifting patterns of HIV encephalitis neuropathology. Neurotox. Res. 8, 51-61.
16. Factor S. A., Podskalny G. D. and Barron K. D. (1994) Persistent neuroleptic-induced rigidity and dystonia in aids dementia complex - a clinicopathological case-report. J. Neurol. Sci. 127, 114-120.
17. Ferris M. J., Mactutus C. F. and Booze R. M. (2008) Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci. Biobehav. Rev. 32, 883-909.
18. Ferris M. J., Frederick-Duus D., Fadel J., Mactutus C. F. and Booze R. M. (2009a) The human immunodeficiency virus-1-associated protein, tat(1-86), impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience 159, 1292-1299.
19. Ferris M. J., Frederick-Duus D., Fadel J., Mactutus C. F. and Booze R. M. (2009b) In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission. Synapse 63, 181-185.
20. Garrick N. A. and Murphy D. L. (1980) Species-differences in the deamination of dopamine and other substrates for monoamine-oxidase in brain. Psychopharmacology 72, 27-33.
21. Harrod S. B., Booze R. M., Welch M., Browning C. E. and Mactutus C. F. (2005) Acute and repeated intravenous cocaine-induced locomotor activity is altered as a function of sex and gonadectomy. Pharmacol. Biochem. Behav. 82, 170-181.
22. Harrod S. B., Mactutus C. F., Fitting S., Hasselrot U. and Booze R. M. (2008) Intra-accumbal Tat(1-72) alters acute and sensitized responses to cocaine. Pharmacol. Biochem. Behav. 90, 723-729.
23. Hinkin C. H., Castellon S. A., Hardy D. J., Farinpour R., Newton T. and Singer E. (2001) Methylphenidate improves HIV-1-associated cognitive slowing. J. Neuropsychiatry Clin. Neurosci. 13, 248-254.
24. Horne M. K., Lee J., Chen F., Lanning K., Tomas D. and Lawrence A. J. (2008) Long-term administration of cocaine or serotonin reuptake inhibitors results in anatomical and neurochemical changes in noradrenergic, dopaminergic, and serotonin pathways. J. Neurochem. 106, 1731-1744.
25. Hriso E., Kuhn T., Masdeu J. C. and Grundman M. (1991) Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am. J. Psychiatry 148, 1558-1561.
26. Hudgens M. G., Longini I. M., Vanichseni S., Hu D. J., Kitayaporn D., Mock P. A., Halloran M. E., Satten G. A., Choopanya K. and Mastro T. D. (2002) Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am. J. Epidemiol. 155, 159-168.
27. Hurd Y. L. and Ungerstedt U. (1989) Cocaine: an in vivo microdialysis evaluation of its acute action on dopamine transmission in rat striatum. Synapse 3, 48-54.
28. Kaplan E. H. and Heimer R. (1992) A model-based estimate of HIV infectivity via needle sharing. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 5, 1116-1118.
29. Kalivas P. W. and Duffy P. (1990) Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse 5, 48-58.
30. Lack C. M., Jones S. R. and Roberts D. C. S. (2008) Increased breakpoints on a progressive ratio schedule reinforced by IV cocaine are associated with reduced locomotor activation and reduced dopamine efflux in nucleus accumbens shell in rats. Psychopharmacology 195, 517-525.
31. Larsson M., Hagberg L., Forsman A. and Norkrans G. (1991) Cerebrospinal-fluid catecholamine metabolites in HIV-infected patients. J. Neurosci. Res. 28, 406-409.
32. Marin M. T., Berkow A., Golden S. A., Koya E., Planeta C. S. and Hope B. T. (2009) Context-specific modulation of cocaine-induced locomotor sensitization and ERK and CREB phosphorylation in the rat nucleus accumbens. Eur. J. Neurosci. 30, 1931-1940.
33. Mateo Y., Lack C. M., Morgan D., Roberts D. C. S. and Jones S. R. (2005) Reduced dopamine terminal function and insensitivity to cocaine following cocaine binge self-administration and deprivation. Neuropsychopharmacology 30, 1455-1463.
34. Nader M. A., Morgan D., Gage H. D., Nader S. H., Calhoun T. L., Buchheimer N., Ehrenkaufer R. and Mach R. H. (2006) PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat. Neurosci. 9, 1050-1056.
35. Nath A. (2010) Human Immunodeficiency Virus-associated neurocognitive disorder: pathophysiology in relation to drug addiction. Ann. N. Y. Acad. Sci. 1187, 122-128.
36. National Institute on Drug Abuse (2009) NIDA Infofacts: Crack and Cocaine.
37. Obermann M., Kuper M., Kastrup O., Yaldizli O., Esser S., Thiermann J., Koutsilieri E., Arendt G., Diener H. C. and Maschke M. (2009) Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV. J. Neurol. 256, 948-953.
38. Paul R., Cohen R., Navia B. and Tashima K. (2002) Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neurosci. Biobehav. Rev. 26, 353-359.
39. Quinton M. S. and Yamamoto B. K. (2006) Causes and consequences of methamphetamine and MDMA toxicity. Aaps J. 8, E337-E347.
40. Sabeti J., Gerhardt G. A. and Zahniser N. R. (2003) Individual differences in cocaine-induced locomotor sensitization in low and high cocaine locomotor-responding rats are associated with differential inhibition of dopamine clearance in nucleus accumbens. J. Pharmacol. Exp. Ther. 305, 180-190.
41. Schmitt K. C., Zhen J., Kharkar P., Mishra M., Chen N., Dutta A. K. and Reith M. E. A. (2008) Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties. J. Neurochem. 107, 928-940.
42. Silvers J. M., Aksenov M. Y., Aksenova M. V., Beckley J., Olton P., Mactutus C. F. and Booze R. M. (2006) Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains. J. Neurovirol. 12, 140-145.
43. Theodore S., Cass W. A. and Maragos W. F. (2006) Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum. Neuroscience 137, 925-935.
44. Wallace D. R., Dodson S., Nath A. and Booze R. M. (2006) Estrogen attenuates gp120-and tat(1-72)-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59, 51-60.
45. Westerink B. H. and Van Putten F. M. (1987) Simultaneous determination of the rates of synthesis and metabolism of dopamine in various areas of the rat brain: application to the effects of (+)-amphetamine. Eur. J. Pharmacol. 133, 103-110.
46. Yamamoto B. K. and Raudensky J. (2008) The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J. Neuroimmune Pharmacol. 3, 203-217.
47. Zahniser N. R. and Sorkin A. (2009) Trafficking of dopamine transporters in psychostimulant actions. Semin. Cell Dev. Biol. 20, 411-417.
48. Zetterstrom T., Sharp T. and Ungerstedt U. (1986) Further evaluation of the mechanisms by which amphetamine reduces striatal dopamine metabolism - A brain dialysis study. Eur. J. Pharmacol. 132, 1-9.
49. Zhu J., Mactutus C. F., Wallace D. R. and Booze R. M. (2009a) HIV-1 Tat protein-induced rapid and reversible decrease in [H-3]dopamine uptake: dissociation of [H-3]dopamine uptake and [H-3]2 beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35, 428) binding in rat striatal synaptosomes. J. Pharmacol. Exp. Ther. 329, 1071-1083.
50. 1-86 on Modulation of Dopamine Transporter Function. 2009 Neuroscience Meeting Planner. Society for Neuroscience, Chicago, IL. Online.